Browse > Article

Development of Vaccine Delivery System and Challenges  

Jung, Hyung-Il (Department of Biotechnology, Yonsei University)
Kim, Jung-Dong (Department of Biotechnology, Yonsei University)
Kim, Mi-Roo (Department of Biotechnology, Yonsei University)
Dangol, Manita (Department of Biotechnology, Yonsei University)
Publication Information
KSBB Journal / v.25, no.6, 2010 , pp. 497-506 More about this Journal
Abstract
Vaccine is a protective clinical measure capable of persuading immune system against infectious agents. Vaccine can be categorized as live attenuated and inactivated. Live attenuated vaccines activate immunity similar to natural infection by replicating living organisms whereas inactivated vaccines are either whole cell vaccines, eliciting immune response by killed organisms,or subunit vaccines, stimulating immunity by non-replicating sub cellular parts. The components of vaccine play a critical role in deciding the immune response mediated by the vaccine. The innate immune responds against the antigen component. Adjuvants represent an importantcomponent of vaccine for enhancing the immunogenicity of the antigens. Subunit vaccines with isolated fractions of killed and recombinant antigens are mostly co-administered with adjuvants. The delivery system of the vaccine is another essential component to ensurethat vaccine is delivered to the right target with right dosage form. Furthermore, vaccine delivery system ensures that the desired immune response is achieved by manipulating the optimal interaction of vaccine and adjuvantwith the immune cell. The aforementioned components along with routes of administration of vaccine are the key elements of a successful vaccination procedure. Vaccines can be administered either orally or by parenteral routes. Many groups had made remarkable efforts for the development of new vaccine and delivery system. The emergence of new vaccine delivery system may lead to pursue the immunization goals with better clinical practices.
Keywords
Adjuvant; Vaccine delivery; Edible vaccine; Transdermal delivery; Microneedle;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Seo, K. Y., S. J. Han, H. R. Cha, S. U. Seo, J. H. Song, S. H. Chung, and M. N. Kweon (2010) Eye Mucosa: An Efficient Vaccine Delivery Route for Inducing Protective Immunity. J. Immunol. 185: 3610-3619.   DOI   ScienceOn
2 Chen, M. W., T. J. Cheng, Y. Huang, J. T. Jan, S. H. Ma, A. L. Yu, C. H. Wong, and D. D. Ho (2008) A consensushemagglutinin- based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. USA 105: 13538-13543.   DOI   ScienceOn
3 Un, K., S. Kawakami, R. Suzuki, K. Maruyama, and F. Yamashita (2010) Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials 31: 7813-7826.   DOI   ScienceOn
4 Laurent, P. E., S. Bonnet, P. Regolini, P. Alchas, J. A. Mikszta, R. Pettis, and N. G. Harvey (2007) Evaluation of the clinical performance of new intradermal vaccine administration technique and associated delivery system. Vaccine 25: 8833-8842.   DOI   ScienceOn
5 Nohria, A. and R. H. Rubin (1994) Cytokines as potential vaccine adjuvants. Biotherapy 7: 261-269.   DOI   ScienceOn
6 Men, Y., H. P. Merkle, B. Gander, and G. Corradin (1996) Induction of sustained and elevated immune responses to weakly immunogenic synthetic malaria peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14: 1442-1450.   DOI   ScienceOn
7 Reddy, S. T., A. J. van der Vlies, E. Simeoni, V. Angeli, G. J. Randolph, C. P. O'Neil, L. K. Lee, M. A. Swartz, and J. A. Hubbell (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotech. 25: 1159-1164.   DOI   ScienceOn
8 Sandhu, J. S., S. F. Krasnyanski, L. L. Domier, S. S. Korban, M. D. Osadjan, and D. E. Buetow (2000) Oral immunization of mice with transgenic tomato fruit expressingrespiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res. 9: 127-135.   DOI   ScienceOn
9 Singh, M. and D. T. O'Hagan (2003) Recent advances in veterinary vaccine adjuvants. Int. J. for Parasitol. 33: 469-478.   DOI   ScienceOn
10 Ahsan, F., I. P. Rivas, M. A. Khan, and A. I. Torres Suarez (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J. Control. Release 79: 29-40.   DOI
11 Leak, L. V. (1971) Studies on the permeability of lymphatic capillaries. J. Cell Biol. 50: 300-323.   DOI   ScienceOn
12 Swartz, M. A., D. A. Berk, and R. K. Jain (1996) Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am. J. Physiol. 270: H324-329.
13 Edelman, R. (1994) Vaccine adjuvants. Rev. infect Dis. 24: 2421-2428.
14 Gupta, R. K. (1998) Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32: 155-172.   DOI   ScienceOn
15 Lewis, P. A. and D. Loomis (1924) Allergic irritability. The formation of anti-sheep hemolytic amboceptor in the normal and tuberculous guinea pig. J. Exp. Med. 40: 503.   DOI
16 Kenney, R. T., S. A. Frech, L. R. Muenz, C. P. Villar, and G. M. Glenn. (2004) Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351: 2295-2301.   DOI   ScienceOn
17 Kantoff, P. W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, Y. Xu, M. W. Frohlich, and P. F. Schellhammer (2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N. Eng. J. of Med. 363: 411-422.   DOI   ScienceOn
18 Pier, G. B., J. B. Lyczak, and L. M. Wetzler (2004) Immunology, Infection, and Immunity. ASM Press.
19 Janeway, C. A. Jr., P. Travers, M. Walport, and M. J. Shlomchik (2001) Immunobiology. (5th ed.). Garland Publishing.
20 Lee, J. W., J. H. Park, and M. R. Prausnitz (2008) Dissolving microneedles for transdermal drug delivery. Biomaterials 29: 2113-2124.   DOI   ScienceOn
21 Dimitrios, G. K., M. del P. Martin, V. G. Zarnitsyn, S. P. Sullivan, R. W. Compans, M. R. Prausnitz, and L. Skountzou (2009) Transdermal influenza immunization with vaccine-coated microneedle arrays. PLos ONE 4: e4773.   DOI
22 Sullivan, S. P., D. G. Koutsonanos, M. del P. Martin, J. W. Lee, V. Zarnitsyn, S. O. Choi, N. Murthy, R. W. Compans, L. Skountzou, and M. R. Prausnitz (2010) Dissolving polymer microneedle patches for influenza vaccination. Nature Med. 16: 915-920.   DOI   ScienceOn
23 Laurent, P. E., S. Bonnet, P. Alchas, P. Regolini, J. A. Mikszta, R. Pettis, and N. G. Harvey (2007) Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25: 8833-8842.   DOI   ScienceOn
24 Ohta, S., K. Suzuhi, K. Tachibana, and G. Yamada (2003) Microbubble-enhanced sonoporation: efficient gene transduction technique for chick embryos. Genesis 37: 91-101.   DOI   ScienceOn
25 Tezel, A., S. Paliwal, Z. Shen, and S. Mitragotri (2005) Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23: 3800-3807.   DOI   ScienceOn
26 Glenn, G. M., M. Rao, G. R. Matyas, and C. R. Alving (1998) Skin immunization made possible by cholera toxin. Nature 391: 851-852.   DOI   ScienceOn
27 Fechheimer, M., J. F. Boylan, S. Parker, J. E. Sisken, G. L. Patel, and S. G. Zimmer (1987) Transfection ofmammaliancells with plasmid DNA by scrape loading and sonication loading. Proc. Natl. Acad. Sci. USA 84: 8463-8467.   DOI   ScienceOn
28 Jackson, L. A., G. Austin, R. T. Chen, R. Stout, F. DeStefano, G. J. Gorse, F. K. Newman, O. Yu, and B. G. Weniger (2001) Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle free jet injectors. Vaccine19: 4703-4709.   DOI   ScienceOn
29 Weniger, B. G. (2004) New high speed jet injectors for mass vaccination: pros and cons of DCJIs versus MUNJIs. WHO initiative for vaccine research: Global Vaccine Research Forum, Montreux, Switzerland.
30 Giudice, E. L. and J. D. Campbell (2006) Needle-free vaccine delivery. Adv. Drug Deliv. 58: 68-89.   DOI   ScienceOn
31 Mumper, R. J. and Z. Cui (2003) Genetic immunization by jet injection of targeted pDMA coated nanoparticles. Methods 31: 255-266.   DOI   ScienceOn
32 Williams, C. G. (2000) Poliomyelitis: extinct by year 2000: But not over. AAOHIN J. 48: 25-31.
33 Henry, S., D. V. McAllister, M. G. Allen, and M. R. Prausnitz (1998) Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm Sci. 87: 922-925.   DOI   ScienceOn
34 Marquet-Blouin, E., F. B. Bouche, A. Steinmetz, and C. P. Muller (2003) Neutralizing immunogenicity of transgenic carrot (Daucus carota L.) derived measles virus hemagglutinin. Plant Mol. Biol. 51: 459-469.   DOI   ScienceOn
35 Rols, M. P. (2008) Mechanism by which electroporation mediates DNA migration and entry into cells and targeted tissues. Methods Mol. Biol. 423: 19-33.   DOI
36 Escoffre, J. M., T. Portet, L. Wasungu, J. Teissie, D. Dean, and M. P. Rols (2009). What is (still not) known of the mechanism by which electroporation mediates gene transfer and expression in cells and tissues. Mol.Biotechnol. 41: 286-295.   DOI   ScienceOn
37 Bodles-Brakhop, A. M., R. Heller, and R. Draghia-Akli (2009) Electroporation for the Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical Developments. The Am. Soc. of Gene Ther. 17: 589-592.
38 Weber, L. W., W. B. Bowne, J. D. Wolchok, R. Srinivasan, J. Qin, Y. Moroi, R. Clynes, P. Song, J. J. Lewis, and A. N. Houghton (1998) Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102: 1258-1264.   DOI   ScienceOn
39 Kalat, M., Z. Kupcu, S. Schuller, D. Zalusky, M. Zehetner, W. Paster, and T. Schweighoffer (2002) In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res. 62: 5489-5494.
40 Bowne, W. B., R. Srinivasan, J. D. Wolchok, W. G. Hawkins, N. E. Blachere, R. Dyall, J. J. Lewis, and A. N. Houghton (1999) Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190: 1717-1722.   DOI   ScienceOn
41 Liao, J. C., P. Gregor, J. D. Wolchok, F. Orlandi, D. Craft, C. Leung, A. N. Houghton, and P. J. Bergman (2006) Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6: 8-24.
42 Clinical Trials. gov ID NCT00471133.
43 Inovio Pharmaceuticals, Inc. homepage.
44 Pedersen, I. R., T. C. Bog-Hansen, K. Dalsgaard, P. M. H. Heegaard (1992) Iscom immunization with synthetic peptides representing measles virus hemagglutinin. Virus Res. 24: 145-169.   DOI   ScienceOn
45 Barr, I. G., A. Sjolander, and J. C. Cox (1998) ISCOMs and other saponin based adjuvants. Adv. Drug. Deliv. Rev. 32: 247-271.   DOI   ScienceOn
46 Morein, B. K. F. Hu, and Abusugra (2004) Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Del. Rev. 56: 1367-1382.   DOI   ScienceOn
47 Zhao, K., G. X. Li, Y. Y. Jin, H. X. Wei, Q. S. Sun, T. T. Huang, Y. F. Wang, and G. Z. Tong (2010) Preparation and immunological effectiveness of a Swine influenza DNA vaccine encapsulated in PLGA microspheres. J. Microencapsul. 27: 178-186.   DOI   ScienceOn
48 Kang, M. L., C. S. Cho, and H. S. Yoo (2009) Application of chitosan microspheres for nasal delivery of vaccines Biotechnol. Adv. 27: 857-865.   DOI   ScienceOn
49 Kimpen, J. L. and P. L. Ogra (1990) Poliovirus vaccines. A continuing challenge. Pediatr. Clin. North Am. 37: 627-649.   DOI
50 Lambert, P. H. and P. E. Laurent (2008) Intradermal vaccine delivery: Will new delivery systems transform vaccine administration. Vaccine 26: 3197-3208.
51 Dennehy, P. H. (2008) Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 21: 198-208.   DOI   ScienceOn
52 Dalsgaard, K. A. Uttenthal, and T. D. Jones (1997) Plant derived vaccines protects target animals against a viral disease. Nat. Biotechnol. 15: 248-252.   DOI   ScienceOn
53 Chikwamba, R., J. Cunnick, D. Hathaway, J. McMurray, H. Mason, and K. Wang (2002) A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res. 11: 479-493.   DOI   ScienceOn
54 Akasaki. M, T. Takashi, Y. Kita, and W. Tsukada (1987) Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys (L18). Agents Actions 22: 144-150.   DOI   ScienceOn
55 Licciardi, P. V. and J. R. Underwood (2010) Identification of a novel vaccine adjuvant that stimulates and maintains diphtheria toxoid immunity. Vaccine 28: 3865-3873.   DOI   ScienceOn
56 Dalsgaard, K. (1978) A study of the isolation and characterization of the saponin quil A. Evaluation of its adjuvant activity, with a special reference to the application in the vaccination of cattle against foot-and mouth disease. Acta. Vet. Stand 69: 1-40.
57 Newman, M. J., Y. J. Wu, B. H. Gardner, K. K. J. Munroe, D. Leombruno, J. Recchai, C. R. Kensiil, and R. T. Coughlin, Saponin adjuvant induction of ovalbuminspecific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148: 2357-2362.
58 Pardoll, D. M. (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol.13: 399-415.   DOI   ScienceOn
59 Odean, M. J., C. M. Frane, M. Van der Vieren, M. A. Tomai, and A. G. Johnson (1990) Involvement of gamma interferon in antibody enhancement by adjuvants. Infect Immun. 58: 427-432.
60 Bliss, J., V. Van Cleave, K. Murray, A. Wiencis, M. Ketchum, R. Maylor, T. Haire, C. Resmini, A. K. Abbas, and S. F. Wolf (1996) IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J. Immunol. 156: 887-894.
61 Luis, C., C. Afonso, T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott (1994)The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.   DOI
62 Le, Moignic and Pinoy (1916) Application to man of vaccines consisting of emulsions in fatty substances (lipo-vaccines). Commp. Rend. Sot. Bio. 29: 352-358.
63 Gkick, R. R. Mischler, B. Finkel, J. U. Que, B. Scarpa, and S. J. Cryz Jr. (1994) Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344: 160-163.   DOI   ScienceOn
64 Jennings, G. T. and M. F. Bachmann (2007) Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr. Mol. Med. 7: 143-155.   DOI   ScienceOn
65 Martin F. B. and T. J. Gary (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10: 787-796.   DOI   ScienceOn
66 Petrovsky N., S. Heinzel, Y. Honda, and A. B. Lyons (2007) New-age vaccine adjuvants: Friend or foe? BioPharm International 20: A24-A33.
67 Hackett, C. J., D. A. Harn, and Jr. (2006) Vaccine Adjuvants: Immunological and Clinical Principles. Humana Press.
68 Allison A. C. and N. E. Byars (1991) Immunological adjuvants: Desirable properties and side-effects. Mol. Immunol. 28: 279-284.   DOI   ScienceOn